氨甲环酸减少膀胱癌根治性膀胱切除术中输血的研究方案
TACT试验为随机双盲安慰剂对照研究,评估氨甲环酸在根治性膀胱切除术中减少红细胞输注的效果。干预组术前给予10 mg/kg负荷剂量后以5 mg/kg/h维持输注,对照组给予等量生理盐水。主要结局为手术开始至术后30天内任何输血,计划随机354例,截至报告已随机147例。
要点
- 根治性膀胱切除术患者输血风险高,氨甲环酸在此场景尚无研究评估。
- TACT试验采用随机双盲安慰剂对照设计,干预组给予氨甲环酸负荷加维持输注。
- 主要结局为手术开始至术后30天内的任何输血,输血决策由设盲的临床医生自行判断。
核心结论
- 氨甲环酸在根治性膀胱切除术中减少输血的效果尚待TACT试验结果验证。
研究设计与样本
- 随机、双盲(外科医生、麻醉医生、患者、数据监查员设盲)、安慰剂对照试验,2013年6月启动。
- 干预组术前给予10 mg/kg氨甲环酸静脉负荷剂量,随后以5 mg/kg/h维持输注。
- 对照组给予与干预组外观无法区分的等量生理盐水。
- 计划随机354例,截至报告时已随机147例。
关键数值与推荐
- 主要结局为手术开始至术后30天内的任何输血。
- 无强制输血标准,输血决策完全由对分组设盲的主治医生自行判断。
- 医生可依据血清血红蛋白浓度和生命体征等所有资源做出输血决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radical cystectomy for bladder cancer is associated with a high risk of needing red blood cell transfusion. Tranexamic acid reduces blood loss during cardiac and orthopedic surgery, but no study has yet evaluated tranexamic acid use during cystectomy. METHODS: A randomized, double-blind (surgeon-, anesthesiologist-, patient-, data-monitor-blinded), placebo-controlled trial of tranexamic acid during cystectomy was initiated in June 2013. Prior to incision, the intervention arm participants receive a 10 mg/kg loading dose of intravenously administered tranexamic acid, followed by a 5 mg/kg/h maintenance infusion. In the control arm, the patient receives an identical volume of normal saline that is indistinguishable from the intervention. The primary outcome is any blood transfusion from the start of surgery up to 30 days post operative. There are no strict criteria to mandate the transfusion of blood products. The decision to transfuse is entirely at the discretion of the treating physicians who are blinded to patient allocation. Physicians are allowed to utilize all resources to make transfusion decisions, including serum hemoglobin concentration and vital signs. To date, 147 patients of a planned 354 have been randomized to the study. DISCUSSION: This protocol reviews pertinent data relating to blood transfusion during radical cystectomy, highlighting the need to identify methods for reducing blood loss and preventing transfusion in patients receiving radical cystectomy. It explains the clinical rationale for using tranexamic acid to reduce blood loss during cystectomy, and outlines the study methods of our ongoing randomized controlled trial. TRIAL REGISTRATIONS: Canadian Institute for Health Research (CIHR) Protocol: MOP-342559; ClinicalTrials.gov, ID: NCT01869413. Registered on 5 June 2013.
引用
- Breau RH, Lavallée LT, Cnossen S, et al. Tranexamic Acid versus Placebo to Prevent Blood Transfusion during Radical Cystectomy for Bladder Cancer (TACT): Study Protocol for a Randomized Controlled Trial. Trials. 2018. PMID: 29716640. doi:10.1186/s13063-018-2626-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。